Name of Trial: Ga DOTA-5G as a Diagnostic Imaging Agent for Metastatic/Advanced Invasive Lobular Breast Cancer (LBC)
Eligible patients: Men and women age ≥ 18 yrs with confirmed presence of metastatic/advanced invasive lobular breast cancer and measurable disease per RECIST (version 1.1). Additional eligibility criteria can be found here.
Description of Trial/Summary:
This is a phase I investigator-initiated study that will investigate [68Ga]Ga DOTA-5G in patients with metastatic/advanced invasive LBC. 30 patients diagnosed with LBC will be enrolled over a 24-month period. We hypothesize that a) [68Ga]Ga DOTA-5G will detect lesions in patients with invasive LBC, b) [68Ga]Ga DOTA-5G will be safe and well tolerated, and that c) [68Ga]Ga DOTA-5G PET/CT is more sensitive than 18F-FDG PET/CT at detecting lesions.
Principal Investigator: Julia Sutcliffe, PhD
Trial Location: Sacramento, California (University of California, Davis)
More information /Trial Contact:
Julia Sutcliffe
916-734-5536
For more information: https://clinicaltrials.gov/study/NCT07020806?term=sutcliffe&rank=2#contacts-and-locations